Exceptional Health.

28/04/2026

21/03/2026

Surgery doesn’t just affect the body. It affects the brain. 🧠

If you’ve ever wondered why recovery sometimes feels harder than expected, why brain fog lingers, or why no one talks about protecting cognition before anesthesia, you are not alone.

I’m Sande Bargeron, a double board-certified Anesthetist(CAA), Physician Assistant, and PhD in natural medicine. After administering anesthesia to more than 10,000 patients, I saw a pattern: we carefully monitor the heart, lungs, and labs, but rarely assess neurological resilience.

That gap is what led me to develop the HARP™ (Holistic Anesthesia Recovery & Preparation) framework and the Neurologic Stress & Recovery Index™ — tools designed to measure risk and support the brain before, during, and after surgery.

In my new book, "Break Through Anesthesia Fog: Protect Your Brain and Heal Faster After Surgery," you’ll discover:

• How anesthesia impacts the brain and body
• Why individualized risk assessment matters
• How to reduce post-op brain fog and emotional shifts
• The role of genetics, like MTHFR mutations, in detoxification and recovery
• Practical HARP protocols to restore cognitive baseline
• How small lifestyle shifts improve outcomes

This book isn’t about fear. It’s about preparation, protection, and measurable resilience.

You deserve to go into surgery informed — and come out stronger.

➡️ Pre-order "Break Through Anesthesia Fog" on Amazon today
🔗 Presale link in bio

21/02/2026

Tiny but powerful, broccoli sprouts pack an impressive punch of sulforaphane that supports your body at the cellular level. 🥦✨

15/02/2026

15/02/2026

15/02/2026

As the understanding of how cells communicate and regulate immune responses advanced, researchers began to notice that certain immune signaling proteins appeared repeatedly across diverse inflammatory conditions associated with systemic inflammation.

Galectin-3 drew sustained scientific attention because of its recurrent association in immune regulation and inflammatory signaling.

As one of several clinician-researchers contributing to early and ongoing research in this field, Dr. Isaac Eliaz, Founder and CEO of Eliaz Therapeutics, has spent decades examining the role of Galectin-3. This work has helped prompt deeper investigation into the protein’s recurring presence under conditions of cellular stress and complex inflammatory states such as sepsis.

15/02/2026

15/02/2026

How to avoid chemicals like PFAS, parabens, phthalates, and lead that may be in your makeup, shampoo, and other cosmetics and personal care items.

18/06/2025

Researchers at Johns Hopkins University have made a potentially game-changing discovery in cancer diagnostics.

They found that fragments of tumor DNA, known as circulating tumor DNA (ctDNA), can be detected in the bloodstream as early as three years before a clinical cancer diagnosis.

This breakthrough opens up an extended window of opportunity for early cancer detection, which is critical for improving survival rates and enabling less invasive treatment options.

The discovery was part of ongoing research into liquid biopsy techniques, which aim to identify cancer through simple blood tests instead of traditional imaging or tissue biopsies.

These ctDNA fragments are shed by tumors into the bloodstream and can carry mutations specific to different types of cancers. Detecting them early may lead to personalized screening strategies, especially for individuals at higher risk.

A study published in Nature Communications (2020) supports this claim.

It discussed how early traces of cancer-related genetic alterations can be detected years before conventional methods would identify the disease.

Such research is the backbone of companies like GRAIL, which are developing multi-cancer early detection tests based on similar principles.

While the detection of tumor DNA years in advance is promising, it's important to note that:

Not all cancers shed enough ctDNA to be detected early.

Further validation across larger and more diverse populations is needed.

There's a risk of false positives or overdiagnosis that must be managed.

Nevertheless, this innovation represents a revolutionary leap forward in the field of oncology, offering hope for earlier intervention and better patient outcomes